Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

As we discussed last quarter, the partnership with Sanofi is a license and collaboration agreement that combines Novavax's ...

Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...

Novavax, a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, is proud to announce an exciting new partnership with the Los Angeles Rams aimed at "Protecting the Rams House" ...

Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

China has reported seven more H9N2 avian flu infections in humans, mostly involving children and all in people whose symptoms ...

The candidate vaccines are part of Novavax's portfolio of recombinant protein-based vaccines that use nanoparticle technology ...

Global Clingwrap Machine Market was... Novavax, Inc. , a global company advancing protein-based vaccines with its Matrix-Mtm adjuvant, today announced that it will participate in the Jefferies London ...

Global Clingwrap Machine Market was... Novavax, Inc. , a global company advancing protein-based vaccines with its Matrix-Mtm adjuvant, today announced that it will participate in the Jefferies London ...